Bioventus (BVS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the impact of the Advanced Rehabilitation divestiture [20][21] - Adjusted EBITDA for the quarter was $37 million, an increase of $8 million or 30% year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the previous year [21][22] - Cash flow from operations totaled approximately $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full year objective of nearly doubling cash flow from operations, achieving a 92% increase for the year [26][28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [23] - Surgical solutions revenue increased by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [23] - Restorative therapies revenue declined by 26% due to the divestiture of the Advanced Rehabilitation business, but organic growth was 10% excluding this impact [24] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged compared to the prior year, with organic growth climbing 10% [24] - The international segment achieved 11% organic growth for the year, supported by a new team and improved commercial execution [24] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [5][10] - In 2026, the company plans to invest approximately $13 million in growth drivers such as PNS, PRP, Ultrasonics, and international business [11][12] - The focus will be on driving above-market growth across core businesses, particularly the HA franchise, while also investing in marketing and R&D to support growth [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and strong foundation, indicating a focus on becoming a $1 billion leading med tech company [5][18] - The company anticipates earnings growth to outpace revenue growth, maintaining an EBITDA margin of approximately 20% for 2026 [17][18] - Management highlighted the importance of leveraging profitable growth to fund future growth drivers, emphasizing a long-term approach to business [40] Other Important Information - The company refinanced its term loan, enhancing liquidity and driving interest expense savings [10] - The company expects net sales for 2026 to range from $600 million to $610 million, with adjusted earnings per share projected at $0.73 to $0.77 [27][28] Q&A Session Summary Question: Growth contribution year-over-year from price in pain treatments - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][35] Question: Assumptions by segment for 2026 growth - Management expects low to mid-single digit growth in restorative therapies and mid to high single digit growth in the pain portfolio, with double-digit growth anticipated in surgical solutions [36][38] Question: Impact of favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [45] Question: Learnings from the PNS pilot phase - Positive feedback was received regarding the technology's power, size, and ease of use, with plans to scale the business aggressively based on these insights [48][50]